Skip to main content
Erschienen in:

31.05.2022 | Original Article

Comprehensive comparison of international prognostic indexes for follicular helper T-cell lymphoma

verfasst von: Yong-Pyo Lee, Sang Eun Yoon, Junhun Cho, Young Hyeh Ko, Hyunji Jo, Seok Jin Kim, Won Seog Kim

Erschienen in: Annals of Hematology | Ausgabe 7/2022

Einloggen, um Zugang zu erhalten

Abstract

In 2016, World Health Organization classification of lymphoid neoplasms separated firmly-follicular helper (Tfh) cell origin lymphomas from peripheral T-cell lymphoma-not specified (PTCL-NOS) based on their unique immunogenic characteristics. Generally, Tfh cell origin lymphoma, which has an approximately 25% incidence, is classified into three categories: angioimmunoblastic T-cell lymphoma (AITL), follicular peripheral T-cell lymphoma (F-PTCL), and nodal peripheral T-cell lymphoma with a T-follicular helper phenotype (nodal PTCL with Tfh cell phenotype). Their prognosis has been estimated using four traditional prognostic tools for T-cell lymphoid malignancies: the international prognostic index (IPI), the prognostic index for peripheral T-cell lymphoma unspecified (PIT), the modified PIT (mPIT) and the international T-cell lymphoma project index. In addition, the AITL score that reflects AITL characteristics well has been introduced recently. However, there are no clear guidelines for evaluating the prognosis of Tfh cell lymphoma. Thus, we performed a comparative analysis to determine which of these five indexes is most suitable for Tfh cell lymphoma. We evaluated the accuracy of classification according to risk score and predicted survival rate. Based on review by lymphoma pathology experts, we enrolled 198 patients diagnosed with Tfh cell lymphoma in this retrospective study. AITL was the most common subtype (n = 168), followed by F-PTCL (n = 21) and nodal PTCL with Tfh cell phenotype (n = 9). The median progression-free survival and overall survival with front-line treatment was 0.8 years (95% confidence interval [CI], 0.6–1.1 years) and 2.9 years (95% CI, 1.6–4.2 years), respectively. The AITL score showed better differentiation than other scoring systems in terms of classification according to risk score. However, for predicting PFS (concordance-index [C-index], IPI vs. PIT vs. modified PIT vs. international T-cell lymphoma project index vs. AITL score; 0.617 vs. 0.605 vs. 0.576 vs. 0.591 vs. 0.592) and OS (C-index, IPI vs. PIT vs. modified PIT vs. international T-cell lymphoma project index vs. AITL score; 0.663 vs. 0.651 vs. 0.612 vs. 0.672 vs. 0.583), the IPI, and the international T-cell lymphoma project index showed better performance. In conclusion, there are unmet needs to develop a prognostic index for Tfh cell lymphoma because its characteristics differ from PTCL-NOS. Although the AITL score reflects Tfh cell-origin lymphoma characteristics well and clearly shows their power of classification according to risk score, there are concerns about accurate prediction of survival outcomes. Therefore, it seems too early to settle on a single scoring system in Tfh cell origin lymphoma. In the future, along with classification, a more effective tool for survival prediction needs to be developed that reflects the specific characteristics of T-cell lymphoma.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat Swerdlow SH et al (2016) The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood 127(20):2375–2390CrossRef Swerdlow SH et al (2016) The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood 127(20):2375–2390CrossRef
2.
Zurück zum Zitat Jaffe ES et al (2008) Classification of lymphoid neoplasms: the microscope as a tool for disease discovery. Blood 112(12):4384–4399CrossRef Jaffe ES et al (2008) Classification of lymphoid neoplasms: the microscope as a tool for disease discovery. Blood 112(12):4384–4399CrossRef
3.
Zurück zum Zitat Lunning MA, Vose JM (2017) Angioimmunoblastic T-cell lymphoma: the many-faced lymphoma. Blood 129(9):1095–1102CrossRef Lunning MA, Vose JM (2017) Angioimmunoblastic T-cell lymphoma: the many-faced lymphoma. Blood 129(9):1095–1102CrossRef
4.
Zurück zum Zitat Yoon SE et al (2021) Comprehensive analysis of clinical, pathological, and genomic characteristics of follicular helper T-cell derived lymphomas. Exp Hematol Oncol 10(1):33CrossRef Yoon SE et al (2021) Comprehensive analysis of clinical, pathological, and genomic characteristics of follicular helper T-cell derived lymphomas. Exp Hematol Oncol 10(1):33CrossRef
5.
Zurück zum Zitat Lemonnier F, Gaulard P, de Leval L (2018) New insights in the pathogenesis of T-cell lymphomas. Curr Opin Oncol 30(5):277–284CrossRef Lemonnier F, Gaulard P, de Leval L (2018) New insights in the pathogenesis of T-cell lymphomas. Curr Opin Oncol 30(5):277–284CrossRef
6.
Zurück zum Zitat Yoon SE et al (2021) Comprehensive analysis of peripheral T-cell and natural killer/T-cell lymphoma in Asian patients: a multinational, multicenter, prospective registry study in Asia. Lancet Reg Health – Western Pac. 10:100126. Yoon SE et al (2021) Comprehensive analysis of peripheral T-cell and natural killer/T-cell lymphoma in Asian patients: a multinational, multicenter, prospective registry study in Asia. Lancet Reg Health – Western Pac. 10:100126.
7.
Zurück zum Zitat Advani RH et al (2021) Outcomes and prognostic factors in angioimmunoblastic T-cell lymphoma: final report from the international T cell Project. Blood 138(3):213–220CrossRef Advani RH et al (2021) Outcomes and prognostic factors in angioimmunoblastic T-cell lymphoma: final report from the international T cell Project. Blood 138(3):213–220CrossRef
8.
Zurück zum Zitat A predictive model for aggressive non-Hodgkin’s lymphoma (1993) N Engl J Med 329(14):987–94. A predictive model for aggressive non-Hodgkin’s lymphoma (1993) N Engl J Med 329(14):987–94.
9.
Zurück zum Zitat Gallamini A et al (2004) Peripheral T-cell lymphoma unspecified (PTCL-U): a new prognostic model from a retrospective multicentric clinical study. Blood 103(7):2474–2479CrossRef Gallamini A et al (2004) Peripheral T-cell lymphoma unspecified (PTCL-U): a new prognostic model from a retrospective multicentric clinical study. Blood 103(7):2474–2479CrossRef
10.
Zurück zum Zitat Went P et al (2006) Marker expression in peripheral T-cell lymphoma: a proposed clinical-pathologic prognostic score. J Clin Oncol 24(16):2472–2479CrossRef Went P et al (2006) Marker expression in peripheral T-cell lymphoma: a proposed clinical-pathologic prognostic score. J Clin Oncol 24(16):2472–2479CrossRef
11.
Zurück zum Zitat Vose J (2005) International Peripheral T-Cell Lymphoma (PTCL) Clinical and pathologic review project: poor outcome by prognostic indices and lack of efficacy with anthracyclines. Blood 106(11):811. Vose J (2005) International Peripheral T-Cell Lymphoma (PTCL) Clinical and pathologic review project: poor outcome by prognostic indices and lack of efficacy with anthracyclines. Blood 106(11):811.
12.
Zurück zum Zitat Cheson BD et al (2014) Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J Clin Oncol 32(27):3059–3068CrossRef Cheson BD et al (2014) Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J Clin Oncol 32(27):3059–3068CrossRef
13.
Zurück zum Zitat Iqbal J et al (2014) Gene expression signatures delineate biological and prognostic subgroups in peripheral T-cell lymphoma. Blood 123(19):2915–2923CrossRef Iqbal J et al (2014) Gene expression signatures delineate biological and prognostic subgroups in peripheral T-cell lymphoma. Blood 123(19):2915–2923CrossRef
14.
Zurück zum Zitat Amador C et al (2019) Reproducing the molecular subclassification of peripheral T-cell lymphoma–NOS by immunohistochemistry. Blood 134(24):2159–2170CrossRef Amador C et al (2019) Reproducing the molecular subclassification of peripheral T-cell lymphoma–NOS by immunohistochemistry. Blood 134(24):2159–2170CrossRef
15.
Zurück zum Zitat Bitansky G et al (2019) Progression of follicular lymphoma within 24 months of first treatment (POD -24) as a predictor of overall survival - a single center retrospective analysis. Blood 134(Supplement_1):1534–1534CrossRef Bitansky G et al (2019) Progression of follicular lymphoma within 24 months of first treatment (POD -24) as a predictor of overall survival - a single center retrospective analysis. Blood 134(Supplement_1):1534–1534CrossRef
16.
Zurück zum Zitat Maria Pamela D et al (2017) Integrative clinicopathological and molecular analyses of angioimmunoblastic T-cell lymphoma and other nodal lymphomas of follicular helper T-cell origin. Haematologica 102(4):e148–e151CrossRef Maria Pamela D et al (2017) Integrative clinicopathological and molecular analyses of angioimmunoblastic T-cell lymphoma and other nodal lymphomas of follicular helper T-cell origin. Haematologica 102(4):e148–e151CrossRef
17.
Zurück zum Zitat Balkwill F (2003) Chemokine biology in cancer. Semin Immunol 15(1):49–55CrossRef Balkwill F (2003) Chemokine biology in cancer. Semin Immunol 15(1):49–55CrossRef
18.
Zurück zum Zitat Nishimoto N, Kishimoto T (2006) Interleukin 6: from bench to bedside. Nat Clin Pract Rheumatol 2(11):619–626CrossRef Nishimoto N, Kishimoto T (2006) Interleukin 6: from bench to bedside. Nat Clin Pract Rheumatol 2(11):619–626CrossRef
19.
Zurück zum Zitat Iliopoulos D, Hirsch HA, Struhl K (2009) An epigenetic switch involving NF-kappaB, Lin28, Let-7 MicroRNA, and IL6 links inflammation to cell transformation. Cell 139(4):693–706CrossRef Iliopoulos D, Hirsch HA, Struhl K (2009) An epigenetic switch involving NF-kappaB, Lin28, Let-7 MicroRNA, and IL6 links inflammation to cell transformation. Cell 139(4):693–706CrossRef
20.
Zurück zum Zitat Eto D et al (2011) IL-21 and IL-6 are critical for different aspects of B cell immunity and redundantly induce optimal follicular helper CD4 T cell (Tfh) differentiation. PLoS One 6(3):e17739CrossRef Eto D et al (2011) IL-21 and IL-6 are critical for different aspects of B cell immunity and redundantly induce optimal follicular helper CD4 T cell (Tfh) differentiation. PLoS One 6(3):e17739CrossRef
21.
Zurück zum Zitat Shang Y et al (2018) B2 microglobulin is a novel prognostic marker of angioimmunoblastic T-cell lymphoma. Sci Rep 8(1):12907CrossRef Shang Y et al (2018) B2 microglobulin is a novel prognostic marker of angioimmunoblastic T-cell lymphoma. Sci Rep 8(1):12907CrossRef
22.
Zurück zum Zitat Ma H et al (2020) Survival benefit in patients with peripheral T-cell lymphomas after treatments with novel therapies and clinical trials. Hematol Oncol 38(1):51–58CrossRef Ma H et al (2020) Survival benefit in patients with peripheral T-cell lymphomas after treatments with novel therapies and clinical trials. Hematol Oncol 38(1):51–58CrossRef
Metadaten
Titel
Comprehensive comparison of international prognostic indexes for follicular helper T-cell lymphoma
verfasst von
Yong-Pyo Lee
Sang Eun Yoon
Junhun Cho
Young Hyeh Ko
Hyunji Jo
Seok Jin Kim
Won Seog Kim
Publikationsdatum
31.05.2022
Verlag
Springer Berlin Heidelberg
Erschienen in
Annals of Hematology / Ausgabe 7/2022
Print ISSN: 0939-5555
Elektronische ISSN: 1432-0584
DOI
https://doi.org/10.1007/s00277-022-04805-y

Kompaktes Leitlinien-Wissen Innere Medizin (Link öffnet in neuem Fenster)

Mit medbee Pocketcards schnell und sicher entscheiden.
Leitlinien-Wissen kostenlos und immer griffbereit auf ihrem Desktop, Handy oder Tablet.

Neu im Fachgebiet Innere Medizin

Wenn die Asthma-Therapie an die Nebenniere geht

Auch unter einer Therapie mit inhalativen Kortikosteroiden kann es zu einer Nebenniereninsuffizienz kommen, wie eine kanadische Kasuistik veranschaulicht.

Junge Brustkrebspatientinnen zum Durchhalten motivieren

Patientinnen, die in jungen Jahren an Hormonrezeptor-positivem Brustkrebs erkranken, neigen dazu, die adjuvante endokrine Therapie auszusetzen oder abzubrechen. Die schlechte Therapiepersistenz scheint die Rückkehr des Tumors zu begünstigen.

Mehr Nierenkrebs bei regelmäßiger Einnahme von NSAR?

In der Allgemeinbevölkerung ist die wiederholte Verordnung von nichtsteroidalen Antirheumatika (NSAR) mit einem leicht erhöhten Nierenkrebsrisiko assoziiert. Dieses Ergebnis einer schwedischen Registerstudie ist allerdings mit einigen Fragezeichen zu versehen. 

Hochrisiko-Spinaliom am besten mit der Mohs-Chirurgie entfernen

Die Mohs-Chirurgie ist zwar mit mehr Aufwand verbunden als die herkömmliche Exzision; für die Versorgung kutaner Hochrisiko-Plattenepithelkarzinome lohnt sich die zeitintensive Technik aber in jedem Fall. Laut einer aktuellen Studie sinkt im Vergleich das Sterberisiko.

EKG Essentials: EKG befunden mit System (Link öffnet in neuem Fenster)

In diesem CME-Kurs können Sie Ihr Wissen zur EKG-Befundung anhand von zwölf Video-Tutorials auffrischen und 10 CME-Punkte sammeln.
Praxisnah, relevant und mit vielen Tipps & Tricks vom Profi.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.